Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.
Stephen Brannan, MD
Advertisement
Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.
Articles by Stephen Brannan, MD
Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Symptoms Are Not Necessarily Signs of Illness: Rethinking Synchronicity in Psychiatry
2
Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders
3
Tardive Dyskinesia in Older Adults: Identification and Management in Long-Term Care Settings
4
Our Readers on the Need to be Nice to Our Pharmacists
5
